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Abstract
Scl/Tal1 confers hemogenic competence and prevents ectopic
cardiomyogenesis in embryonic endothelium by unknown mecha-
nisms. We discovered that Scl binds to hematopoietic and
cardiac enhancers that become epigenetically primed in multipo-
tent cardiovascular mesoderm, to regulate the divergence of
hematopoietic and cardiac lineages. Scl does not act as a pioneer
factor but rather exploits a pre-established epigenetic landscape.
As the blood lineage emerges, Scl binding and active epigenetic
modifications are sustained in hematopoietic enhancers, whereas
cardiac enhancers are decommissioned by removal of active
epigenetic marks. Our data suggest that, rather than recruiting
corepressors to enhancers, Scl prevents ectopic cardiogenesis by
occupying enhancers that cardiac factors, such as Gata4 and
Hand1, use for gene activation. Although hematopoietic Gata
factors bind with Scl to both activated and repressed genes, they
are dispensable for cardiac repression, but necessary for activat-
ing genes that enable hematopoietic stem/progenitor cell devel-
opment. These results suggest that a unique subset of enhancers
in lineage-specific genes that are accessible for regulators of
opposing fates during the time of the fate decision provide a
platform where the divergence of mutually exclusive fates is
orchestrated.
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Introduction
Specification of cell types is dictated by few master regulators that
activate lineage-specific transcriptional networks. This concept is
underscored by studies in which overexpression of a small set of
transcription factors can reprogram fibroblasts (or other cells) into a
variety of cell types that closely resemble pluripotent cells, neurons,
pancreatic beta cells, cardiomyocytes or hematopoietic cells
(Takahashi & Yamanaka, 2006; Ieda et al, 2010; Huang et al, 2011;
Kim et al, 2011; Pereira et al, 2013). Hematopoietic and cardiovascu-
lar systems are important targets for cell-based therapies due to the
high morbidity and mortality associated with blood and heart
diseases; however, so far, in vitro generation of transplantable cells
for treating these diseases has not been successful. Blood cells,
vasculature and the heart share not only an intimate functional
relationship, but also a common origin in Flk1+ mesoderm
(Fehling et al, 2003; Huber et al, 2004; Iida et al, 2005; Kattman
et al, 2006). Although many regulators of the blood and circulatory
system have been discovered, it is unclear how the divergence of
these lineages in multipotent cardiovascular mesoderm is orches-
trated and how their cell identity is solidified. Although several
specific epigenetic modifications have been associated with activa-
tion or repression of the regulatory regions of genes (Cui et al, 2009;
Creyghton et al, 2010; Zentner et al, 2011), to what degree they
cause, or are the consequence of, gene activation/repression by cell
type-specific transcription factors is still unclear.
The embryonic hematopoietic system is established in multiple
waves, starting with the generation of lineage-restricted progenitors
in the yolk sac and culminating in the emergence of multipotent
hematopoietic stem/progenitor cells (HS/PC) in the major vessels in
the yolk sac (Li et al, 2005; Yoshimoto et al, 2011), aorta-gonad
mesonephros (AGM) region (North et al, 1999; De Bruijn et al,
2000; Zovein et al, 2008; Chen et al, 2009; Bertrand et al, 2010;
Boisset et al, 2010; Kissa & Herbomel, 2010) and the placenta
(Rhodes et al, 2008). The Ets factor Etv2/ER71/Etsrp first
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distinguishes the hemato-vascular lineages from cardiac mesoderm
by specifying endothelium (Lee et al, 2008; Sumanas et al, 2008;
Kataoka et al, 2011) and activates the bHLH factor Scl/Tal1, which
confers hemogenic identity to endothelium (Van Handel et al,
2012). Scl also has a less well understood but important function in
repressing the cardiac fate (Schoenebeck et al, 2007; Ismailoglu
et al, 2008; Van Handel et al, 2012). Inducible overexpression of Scl
during ES cell differentiation resulted in the expansion of hemato-
poietic lineage at the expense of cardiac and paraxial mesoderm
(Ismailoglu et al, 2008), while the analysis of Scl knockout (SclKO)
embryos revealed robust generation of ectopic cardiomyocytes in
yolk sac vasculature, verifying a physiological role for Scl in cardiac
repression (Van Handel et al, 2012). The requirement for Scl to
repress cardiogenesis in hemogenic tissues was restricted to early
midgestation of mouse development, suggesting the presence of
epigenetic or other contributing mechanisms that solidify the fate
choice. Scl also prevented misspecification of endocardium and
cushion mesenchymal cells to cardiomyocytes. Although these stud-
ies pointed to a critical requirement for Scl in cardiac repression, it
remained unknown whether Scl or its downstream targets repress
cardiogenesis.
Scl functions in a multi-factor complex with Gata factors 1 or 2,
E2A, Ldb1 and Lmo2 (Wadman et al, 1997) that promotes gene
activation in hematopoietic cells (Tripic et al, 2009; Yu et al, 2009;
Xu et al, 2012). Gata2 functions in HS/PC generation and survival
(De Pater et al, 2013; Gao et al, 2013) whereas Gata1 regulates the
maturation of erythroid, megakaryocytic and eosinophilic lineages
(Bresnick et al, 2012), although there is redundancy between these
factors (Takahashi et al, 2000). Embryos deficient for both Gata1
and Gata2 lack all blood cells, similar to Scl knockout embryos
(Fujiwara et al, 2004). However, it is unknown whether hemato-
poietic Gata factors cooperate with Scl to repress cardiomyogenesis.
Here we show that Scl-dependent activation of hematopoietic
fate and repression of cardiac fate during mesoderm diversification
is accompanied by Scl binding to hematopoietic and cardiac
enhancers that were epigenetically primed for activation in meso-
derm. Our findings suggest that the accessibility and decommis-
sioning of Scl-regulated enhancers is determined by modulation of
active rather than repressive epigenetic modifications and is a
major determinant of available fate choices and developmental
stage specificity of target genes. We discovered a distinct subset of
Scl-regulated enhancers that are also accessible for cardiac tran-
scription factors in mesoderm, and propose that these enhanc-
ers serve as a platform where the fate choice between mutually
exclusive fates is determined. Although hematopoietic Gata
factors can bind with Scl to both activated and repressed
enhancers, their function becomes critical only for activating genes
required for HS/PC emergence from hemogenic endothelium.
Elucidation of the stepwise process of how master regula-
tors exploit the epigenetic landscape to establish hematopoietic or
cardiovascular cell types from multipotent mesoderm provides
new insights into improving directed differentiation and lineage
reprogramming of stem/progenitor cells of these lineages for
regenerative medicine.
Results
Scl specifies mesoderm by binding to genes encoding
hematopoietic and cardiac regulators
To understand how Scl specifies hemogenic endothelium while
simultaneously repressing the cardiac fate, we defined Scl target
genes by combining gene expression and chromatin immunopre-
cipitation sequencing (ChIP-seq) analysis on Flk1+ mesodermal
cells differentiated from mouse ES cells (Supplementary Fig S1A).
Scl binding associated genes (4,393 binding sites associated with
4,158 genes within 200 kb from transcriptional start sites) (Supple-
mentary Table S1A) were intersected with Scl-dependent genes
(592 and 553 genes that were significantly up- or down-regulated
in mesoderm upon Scl expression (P-value < 0.05, fold change
< 1.5, see details in Supplementary Fig S1A–C, Supplementary
Table S1B and C, and Supplementary Materials and Methods).
Integrated analysis showed Scl binding to 57% of the activated and
29% of the repressed genes in mesoderm (Fig 1A, Supplemen-
tary Table S1B and C), which is significantly higher than would
be expected by random chance (P-values 4.08 × 10103 and
3.91 × 1010, respectively). The genes in activated/bound group
were enriched for GO term hematopoiesis, including key hemato-
poietic transcription factors Runx1, Gata2, cMyb and Cfba2t3/Eto2
(Fig 1B–D). The genes in repressed/bound group were enriched
for GO term heart development, including cardiac transcription
▸Figure 1. Scl binds to both its activated and repressed target genes in Flk1+ mesoderm.A Venn diagram showing the number of Scl binding sites and overlap with Scl activated and repressed genes in Flk1+ MES (mesoderm) documents that Scl binds to
both Scl-dependent activated and repressed genes.
B DAVID (Huang et al, 2007) GO enrichment analysis for Scl-bound and activated or Scl-bound and repressed genes shows enrichment of hematopoietic and heart-
related terms, respectively.
C Gene expression heatmaps of selected genes from the bound and activated and bound and repressed groups show activation of key hematopoietic target genes and
repression of key cardiac target genes in Scl-expressing mesoderm as compared to Scl-deficient mesoderm. Control [Scl+/hCD4, divided into Scl-expressing (Scl+) and
non-expressing cells (Scl)] and SclKO EBs are shown.
D Scl and control IgG ChIP-seq tracks show examples of Scl binding sites near hematopoietic (Runx1 and Gata2) and cardiac (Gata4 and Gata6) genes in Flk1+
mesoderm (MES).
E Verification of Scl binding sites marked with asterisks in (D) using ChIP-PCR, average enrichment of at least three independent biological experiments over negative
control region (chr16: 92230219–92230338) with SEM are shown.
F Verification of Scl-dependent gene expression using qRT–PCR. Average of three biological replicates with SD are shown.
G Venn diagrams show the number of potential ‘extended activated’ and ‘extended repressed’ Scl target genes by intersecting genes associated with Scl binding in Flk1+
MES with Scl activated and repressed genes from day 4 EBs, E9.5 yolk sac, placenta and endocardium (Van Handel et al, 2012).
H Heatmaps show Scl binding to majority of activated hematopoietic and repressed cardiac transcription factors and other proteins. See also Supplementary Fig S1 and
Supplementary Table S1A–E.
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factors Gata4, Gata6 and Tbx3 (Fig 1B–D). Quantitative RT–PCR
and ChIP–PCR verified Scl-dependent expression and Scl binding
with both activated and repressed genes (Fig 1E and F).
As the expression analysis in day 4 EB Flk1+ cells was
limited to genes that were immediately activated or repressed
upon Scl induction in mesoderm, we extended the analysis of
Scl-dependent genes to those that became differentially expressed
in endothelium in the yolk sac or the placenta, or endocardium
in the heart in SclKO embryos (Van Handel et al, 2012). This
analysis yielded an extended list of 3,709 Scl-dependent activated
and 2,839 Scl-dependent repressed genes, of which 1,100 (29.6%)
and 715 (25.2%) (Supplementary Fig S1A, Supplementary Table S1D
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and E) were bound by Scl in Flk1+ mesoderm (Fig 1G), which is
significantly higher than would be randomly expected (P-values
2.75 × 1083 and 4.44 × 1025, respectively). Analysis of the
‘extended activated’ genes showed that Scl binds to regulatory
regions of the majority (33/39) of known hematopoietic transcrip-
tion factors, many (48/57) surface markers and other proteins
characteristic of nascent HS/PCs and hemogenic endothelium such
as CD41 (Itga2b) and Cdh5 (VE-cadherin) (Fig 1H). Scl binding
was also associated with many (18/29) cardiac transcription
factors (Gata4, Gata6, Hand1 and Tbx5), PDGFRa, a marker for
cardiogenic mesoderm and ectopic cardiomyogenic precursors in
SclKO embryos (Van Handel et al, 2012), and cardiomyocyte
contractile proteins (Tnnc1, Tnnt2, Tnni1 and Ttn) (Fig 1H).
These data showed that during mesoderm diversification, Scl
binds to a broad network of genes that govern hematopoietic and
cardiac development, including the master transcription factors of
each lineage.
To verify that the ES cell in vitro differentiation system recapitu-
lates ectopic cardiomyogenesis in Scl-deficient endothelial precur-
sors, SclKO and wild-type ES cells were differentiated toward
mesodermal lineages and assayed for differentiation potential and
gene expression. SclKO ES cells with doxycycline-inducible Scl over-
expression (SclKOiScl) were included to assess whether reintroduc-
tion of Scl is sufficient to reverse the phenotype. As expected, both
wild-type and SclKOiScl EBs, but not SclKO EBs, could generate
CD41+c-Kit+ hematopoietic progenitors by day 7 (Supplementary
Fig S1D). Likewise, Tie2+CD31+ endothelial precursors isolated
from day 4.75 EBs from wild-type and SclKOiScl cells, but not SclKO
cells, robustly generated CD45+CD11b+/ hematopoietic cells on
OP9 stroma (Supplementary Fig S1E). SclKO Tie2+CD31+ endothe-
lial precursors readily differentiated to troponin T-expressing cardio-
myocytes, whereas re-expression of Scl abolished the ectopic
cardiogenic potential in ES cell-derived endothelial cells (Supple-
mentary Fig S1E). These data were reinforced by qRT–PCR analysis
that verified the lack of expression of hematopoietic transcription
factors and ectopic induction of cardiac factors in Scl-deficient endo-
thelium, and rescue of these molecular defects by Scl overexpres-
sion (Supplementary Fig S1F). These data validate the ES cell
in vitro differentiation system as a suitable model to study Scl-
dependent cardiac repression and ectopic cardiogenesis from
endothelial precursors.
Scl regulates mesodermal fate diversification via
pre-established enhancers
Analysis of genomic locations of Scl binding showed that the major-
ity of Scl binding sites in Flk1+ mesoderm reside away from tran-
scriptional start site (TSS) (Fig 2A), suggesting that Scl functions
through enhancer elements. This was most pronounced in the
repressed genes, where only 3% of Scl binding sites were found
within 5 kb of TSS. We thus correlated Scl mesodermal binding sites
with published datasets for cardiac enhancers, including the Vista
Enhancer database that contains in vivo experimentally verified
enhancers (Visel et al, 2007) and ChIP-seq analysis for co-activator
p300, a marker of enhancers (Visel et al, 2009), in E11.5 mouse
hearts (Blow et al, 2010). Intersecting these data with Scl binding
sites in Flk1+mesoderm revealed Scl binding in 10–16% of all puta-
tive cardiac enhancers, which is significantly (P = 8.6E5) higher
than the overlap with enhancers in other tissues (Fig 2B and C).
Analysis of well-established enhancers of cardiac transcription
factors Myocardin and Nkx2.5 (Fig 2D) (Lien et al, 1999; Creemers
et al, 2006) and hematopoietic regulators Runx1 (+23 enhancer)
(Nottingham et al, 2007) and Gata2 (+9.5 enhancer) (Wozniak et al,
2007; Gao et al, 2013) (Supplementary Fig S2A) showed clear over-
lap with Scl binding.
To assess the epigenetic state of Scl-bound enhancers, 4,393 Scl
mesodermal binding sites were assessed for the average levels of
histone modifications associated with enhancers (H3K4me1) and
active enhancers (H3K4me1 and H3K27ac) (Creyghton et al, 2010;
Wamstad et al, 2012) during ES cell differentiation to cardiomyo-
cytes. In ES cells, Scl mesodermal binding sites were largely devoid
of H3K4me1 and H3K27ac; however, in Flk1+ mesoderm they had
acquired high levels of H3K4me1 and some H3K27ac, which were in
part retained during differentiation into cardiac progenitors and
cardiomyocytes (Fig 2E and F). Analysis of the average H3K4me1
and H3K27ac levels around Scl binding sites in other mesodermal
tissues (limb, fibroblasts) showed no enrichment (Fig 2F). This indi-
cates that the regulatory regions to which Scl binds become epige-
netically primed for activation specifically in Flk1+mesoderm.
We next asked whether Scl is required for depositing active
histone marks at hematopoietic and/or cardiac enhancers or
whether these enhancers have been epigenetically pre-established
prior to Scl binding. ChIP-seq analysis for histone H3K4me1 and
▸Figure 2. Scl binds to enhancers that have been primed for activation in mesoderm.A Distribution of Scl binding sites relative to TSS in Scl-bound activated or repressed genes shows that majority of Scl binding sites locate away from TSS. Chi-square
test was used to assess differences in the distribution.
B Percent of tissue-specific enhancers validated by LacZ reporter mice (Vista enhancer browser) that overlap with Scl MES binding sites shows that Scl binds to
experimentally verified heart enhancers more often compared to enhancers from other tissues.
C Percent of Scl MES binding sites that overlap with heart enhancers in E11.5 embryos defined by p300 binding (Blow et al, 2010) is higher than overlap with
enhancers from other tissues.
D Scl MES binding sites overlap with experimentally verified heart-specific enhancers upstream of Myocardin and Nkx2.5 genes and with hematopoietic enhancers
within Runx1 and Gata2 genes.
E Percent of enhancers from different cardiac developmental stages identified by H3K4me1 (enhancers) and H3K4me1 combined with H3k27ac (active enhancers)
(Wamstad et al, 2012) that overlap with Scl MES binding sites.
F Average H3K4me1 (left) and H3K27ac (right) profiles around all 4,393 Scl binding sites show tissue-specific enrichment in Flk1+ mesoderm (MES), cardiac precursors
(CP) and cardiomyocytes (CM) but not in ESC (mouse ES cells) mouse embryonic fibroblasts (MEF) and embryonic limbs (LIMB).
G Correlation analysis of H3K4me1 (left) and H3K27ac (right) levels between WT and SclKO MES and ES cells and MES (Wamstad et al, 2012) around 4,393 Scl binding
sites shows that establishment of these marks occurs independently of Scl.
H Scl, H3K4me1 and H3K27ac ChIP-seq tracks show comparable levels of H3K4me1 and H3K27ac in WT and SclKO mesoderm around cardiac (Gata6, Tbx5) and
hematopoietic (Eto2, Gfi1b) genes.
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H3K27ac in WT and SclKO Flk1+mesoderm evidenced co-localization
of the active marks across all Scl binding sites (Fig 2G) including
cardiac and hematopoietic genes (Fig 2H) in both cell lines.
Although H3K27ac levels were generally lower and this mark was
not present in all hematopoietic or cardiac enhancers, there was no
significant difference in H3K27ac levels at Scl mesodermal binding
sites in WT and SclKO Flk1+mesoderm (Fig 2G and H). These results
show that Scl is not required for the establishment of active enhancer
marks in mesoderm, suggesting that these enhancers have become
primed for activation in multipotent cardiovascular mesoderm to
pave the way for Scl action.
To investigate whether the epigenetically primed status of
enhancers is necessary for Scl binding, we induced Scl expression
ectopically in SclKOiScl ES cells and compared Scl binding in these
cells to that in Flk1+ mesoderm in wild-type and SclKOiScl cells.
While inducible Scl was faithfully bound to the hematopoietic and
cardiac enhancers in mesoderm, minimal binding was observed in
ES cells (Supplementary Fig S2). Notably, the few binding sites
where ectopically expressed Scl was able to bind in ES cells also
harbored H3K4me1, whereas the key hematopoietic and cardiac
enhancers were devoid of both Scl binding and H3K4me1 (Supple-
mentary Fig S2). These data imply that Scl binding is tightly devel-
opmentally controlled, and at least in part determined by epigenetic
status of the enhancers.
Repression of cardiac enhancers by Scl occurs transiently during
mesoderm diversification
Since Scl is required only during a brief developmental window in
midgestation to repress cardiogenesis in hemogenic tissues (Van
Handel et al, 2012), we assessed whether Scl binding to cardiac
enhancers is maintained in hematopoietic cells later in develop-
ment. Intersecting Scl binding sites in Flk1+ mesoderm with previ-
ously published Scl binding sites in ES cell-derived hematopoietic
progenitor cell line (HPC7) (Wilson et al, 2010) or fetal liver
erythroblasts (Kassouf et al, 2010) showed that many Scl binding
sites are developmental stage specific (Fig 3A). GO enrichment
analysis revealed enrichment of heart-related terms only with Flk1+
mesoderm-specific peaks (Fig 3B) and genes (Supplementary Fig
S3A). Analysis of Scl ChIP-seq tracks for cardiac regulators Gata4,
Nkx2-5 and Myocardin verified Scl binding only in Flk1+mesoderm
(Fig 3C). To confirm that different methods for ChIP-seq analysis
between labs did not account for the difference, we performed Scl
ChIP-seq on MEL cells (mouse erythroleukemia line) and verified
the absence of Scl binding in cardiac genes (Fig 3C, Supplementary
Fig S3B). In comparison, Scl binding sites shared between different
stages were enriched for hematopoiesis-related terms, and included
major hematopoietic transcription factors (e.g. Gata1, Gata2, Lyl1,
Gif1b, Runx1 and Myb) (Fig 3C, Supplementary Fig S3A and B).
While Flk1+ mesoderm-specific peaks were rarely found within
5 kb of TSS (Fig 3D), 46% of the HPC7 or 34% of the erythroid cell-
specific peaks were located within 5 kb to TSS. These data suggest
that Scl binding extends from distant enhancers to promoters as
hematopoiesis progresses.
Since Scl was no longer bound to cardiac enhancers in hematopoi-
etic cells, we assessed whether the epigenetic landscape in Scl bind-
ing sites was modified upon differentiation of mesoderm to
hematopoietic cells. Combinatorial clustering of Scl mesodermal
binding sites based on H3K4me1 patterns in mesoderm, hematopoi-
etic progenitors (HPC7) and erythroid cells (MEL) revealed two major
clusters. Although the majority of Scl binding sites harbored
H3K4me1 in mesoderm, this enhancer mark was lost in Scl binding
sites in cluster L (= Loss of H3K4me1) but retained in cluster
R (= Retention of H3K4me1) as hematopoietic development
progressed. The gradual loss of H3K4me1 enrichment from HPC7 to
MEL in cluster L strongly correlated with the loss of H3K27ac and Scl
binding, while Scl binding sites in cluster R retained H3K4me1,
H3K27ac and Scl binding (Fig 3E). The peaks in cluster L were
enriched for cardiac GO terms and included key cardiac regulators
Gata4, Gata6 and Myocardin (Fig 3E, Supplementary Fig S3B), while
Scl peaks in cluster R were enriched for hematopoietic-related GO
terms and included hematopoietic regulators Gata1, Gata2, Lyl1 and
Runx1 (Fig 3E, Supplementary Fig S3B). The opposite was observed
in the cardiomyocyte cell line HL1, in which the enhancers of key
hematopoietic regulators lost H3K4me1 and H3K27ac, while the
enhancers of regulators of cardiomyocyte differentiation maintained
these active marks (Supplementary Fig S3B). These results imply that
the epigenetic landscape becomes dynamically remodeled in unused
enhancers upon mesodermal fate diversification to blood and heart.
Decommissioning of Scl-regulated cardiac enhancers is
associated with loss of active epigenetic marks rather than gain
of repressive marks
We next investigated whether the active epigenetic marks in Scl-
regulated cardiac enhancers are replaced by repressive marks in
▸Figure 3. Scl binding to cardiac enhancers occurs transiently in mesoderm.A Venn diagram showing overlaps of Scl binding sites in different developmental stages—Flk1+ MES, fetal liver (FL) erythroblast cells (Kassouf et al, 2010) and
hematopoietic progenitors (HPC7) (Wilson et al, 2010) (left)—shows that majority of Scl binding sites are developmental stage specific. Examples of developmental
stage-specific Scl-bound genes are shown (right).
B GREAT (McLean et al, 2010) analysis of significantly enriched GO terms in Mouse Phenotype category for all common, Flk1+ MES-specific, HPC7-specific and FL
erythroblast-specific peaks shows enrichment of heart-related terms only among Flk1+ MES-specific peaks.
C ChIP-seq tracks with Scl binding in Flk1+ MES, HPC7, FL erythroblasts and MEL (mouse erythroleukemia) cells around cardiac (Gata4, Myocd, Nkx2.5) and
hematopoietic (Gata1, Gata2 and Lyl1) genes show that binding to cardiac genes occurs only in mesoderm, while binding to hematopoietic genes is maintained
throughout hematopoietic development.
D Comparison of the location of developmental stage-specific Scl binding sites relative to TSS shows that Scl binding near TSS occurs more often in later hematopoietic
development compared to mesoderm.
E Heatmaps of combinatorial clustering of H3K4me1 around Scl mesodermal binding sites in MES, HPC7 and MEL reveal two major clusters: Cluster L loses H3K4me1,
H3K27ac and Scl binding during hematopoietic differentiation and is enriched for genes involved in heart development; cluster R retains H3K4me1, H3K27ac and Scl
binding during hematopoietic differentiation and is enriched for hematopoiesis-related genes. Selected GO terms among top 10 most enriched are shown.
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hematopoietic cells to solidify the fate choice. Analysis of Ter119
erythroid cells for several histone marks (ENCODE project and
Kowalczyk et al, 2012) in Scl mesodermal binding sites confirmed
a strong correlation between Scl binding and retention of the
active histone marks H3K4me1 and H3K27ac in Cluster R, and loss
of these marks in Cluster L (Fig 4A), also in erythroid cells in vivo.
A candidate for a repression mechanism was Polycomb-mediated
deposition of H3K27me3, which has been associated with silencing
of both promoters and enhancers (Harmston & Lenhard, 2013).
Moreover, Scl has been shown to interact with Ezh2, a core
component of the Polycomb repressive complex 2 (PRC2) (Pinello
et al, 2014). Analysis of H3K27me3 ChIP-seq data provided no
evidence of H3K27me3 acquisition at Scl binding sites in erythroid
cells in either Cluster R or L (Fig 4A). ChIP-seq tracks around
cardiac genes Gata4, Gata6 and Tbx5 confirmed the lack of
H3K27me3 at Scl binding sites in ES cells, mesoderm and erythroid
cells (Fig 4B). However, H3K27me3 was observed at the TSS of
some Scl-regulated genes (Fig 4B). Comparison of H3K27me3
levels in Scl-bound extended activated and extended repressed
genes (see Fig 1, Supplementary Table S1D and E) in erythroid
cells revealed an increase in H3K27me3 at the TSS of repressed
genes, while H3K27ac was more enriched at the TSS of activated
genes (Fig 4C). These data suggested that Polycomb may contrib-
ute to the silencing of Scl-regulated genes at promoters, and raised
the question whether Scl binding at enhancers is required for
bringing PRC2 complex to promoters via chromosomal looping.
ChIP-seq analysis for Ezh2 in mesoderm showed strong correlation
between Ezh2 binding and H3K27me3 at TSS; however, there was
no enrichment of Ezh2 at Scl binding sites (Fig 4E). Moreover,
there was no difference in the ability to recruit Ezh2 to the TSS
of Scl-regulated genes in WT versus SclKO Flk1+ mesoderm (Fig 4D
and F). Altogether, these data imply that although Polycomb-
mediated repression may contribute to the silencing of cardiac
genes in the blood lineage, it is not a major factor governing accessi-
bility to Scl-bound enhancers in mesoderm or their derivatives,
and the failure to repress cardiac genes in Scl-deficient mesoderm
is not caused by lack of Ezh2 recruitment to these genes.
We next assessed whether the repressive histone modification
H3K9me3 is acquired at the decommissioned enhancers during hema-
topoietic differentiation. The average levels of H3K9me3 were slightly
higher in cluster L binding sites than in cluster R binding sites in three
hematopoietic cell types (Ter119 erythroid cells, Fig 4A, Supplemen-
tary Fig S4B, and G1E embryonic erythroid cell line and Ch12 B
lymphoid cells, Supplementary Fig S4A and B). However, analysis of
H3K9me3 around key cardiac genes did not show specific enrichment
for H3K9me3 at Scl-bound enhancers (Supplementary Fig S4C).
These data imply that although regions around some Scl mesodermal
binding sites acquire H3K9me3 during hematopoietic differentiation,
deposition of H3K9me3 is unlikely the predominant mechanism that
initiates Scl-mediated cardiac repression.
As DNA methylation can restrict transcription factor binding to
its target DNA (Blattler & Farnham, 2013), we asked whether
changes in DNA methylation mediate the inactivation of Scl-
regulated cardiac enhancers in hematopoietic cells. Comparison of
the average DNA methylation levels at Scl mesodermal binding sites
associated with extended list of Scl activated or repressed genes in
genome-wide methylation datasets from mouse ES cells (Habibi
et al, 2013), bone marrow, heart, pancreas and skin (Hon et al,
2013), showed that Scl binding sites are on average hypomethylated
compared to the surrounding regions (Supplementary Fig S4D).
Nevertheless, both Scl’s extended activated and repressed target
genes showed a general increase in DNA methylation within 200 kb
of Scl binding sites from ES cells to all adult cell types analyzed
(Supplementary Fig S4E). The methylation levels in Scl extended
activated genes were lower in the bone marrow compared to other
tissues, while the extended repressed genes showed lower methyla-
tion in the heart (Supplementary Fig S4E).
To investigate whether Scl initiates differential methylation in
mesoderm, we performed RRBS (reduced representation bisulfite
sequencing) in ES cells, WT and SclKO Flk1+ mesodermal cells,
and MEL cells. Global covariance analysis showed that major
changes in DNA methylation occur later in hematopoietic develop-
ment rather than in mesoderm (Supplementary Fig S4F). Intersec-
tion of RRBS data with Scl mesodermal binding sites showed no
difference in methylation levels in ES cells and WT and SclKO
Flk1+ mesoderm; only MEL cells had higher DNA methylation
(Supplementary Fig S4G). Thus, while DNA methylation may
contribute to the silencing of Scl target genes in differentiated cells,
this occurs later in development and is not centered at Scl-bound
enhancers. These data imply that DNA methylation is not a
primary mechanism that silences Scl-regulated cardiac enhancers
during hematopoietic specification.
Our analysis of known repressive histone marks did not provide
evidence that Scl-regulated enhancers would be actively silenced
during mesodermal lineage diversification, but rather implied that
gain and loss of active epigenetic marks is the key determinant
◀ Figure 4. Scl-mediated repression of cardiac genes cannot be explained by Scl-dependent corepressor recruitment.A Heatmaps of H3K4me1, H3K27ac, H3K27me3 and H3K9me3 histone modifications in FL erythroblasts around Scl MES binding sites in cluster L and cluster R show no
gain of common repressive histone marks in cluster L.
B H3K27me3 ChIP-seq tracks in ES cells (ESC), Flk1+ mesoderm (MES) and FL erythroblasts (Ery) show that cardiac genes Gata6, Tbx5 and Gata4 harbor H3K27me3 at
the TSS (pink) but not at Scl binding sites (gray).
C Average H3K27me3 (left) and H3K27ac (right) levels in FL erythroblasts around the TSS of extended list of Scl activated and repressed genes show that Scl repressed
genes have on average more H3K27me3 and less H3K27ac as compared to Scl activated genes.
D Ezh2 ChIP-seq tracks in WT and SclKO mesoderm showing that Ezh2 recruitment to the TSS of cardiac genes Gata6, Tbx5 and Gata4 is not Scl dependent.
E Average Ezh2 enrichment in WT (left) and SclKO mesoderm (right) for inactive enhancers (defined by having H3K4me1 and H3K27me3 modifications (Wamstad et al,
2012) and distance greater than 5 kb from TSS) and for Scl binding sites shows no Ezh2 enrichment at Scl binding sites.
F Average Ezh2 enrichment at the TSS of extended list of Scl activated and repressed genes is similar in WT (left) and SclKO mesoderm (right).
G Heatmaps of Lsd1 enrichment in ES cells, WT and SclKO mesoderm and in granulocytes (Gr) (Kerenyi et al, 2013) in cluster L and cluster R show co-localization of Lsd1
binding with Scl binding sites and reveal that recruitment of Lsd1 can happen independently of Scl.
H Lsd1 ChIP-seq tracks (ES cells, WT and SclKO Flk1+ mesoderm and granulocytes) and H3K4me1 ChIP-seq track (granulocytes) show that Lsd1 enrichment coincides
with Scl MES binding sites nearby cardiac genes Gata6 and Myocd in WT and SclKO Flk1+ mesoderm.
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that governs tissue-specific access to these enhancers. We thus
assessed whether the recruitment of Lsd1, a lysine-specific demeth-
ylase 1 that decommissions enhancers by removing H3K4me1
(Whyte et al, 2012), to cardiac enhancers is interrupted in the
absence of Scl. Comparison of ChIP-seq data of Lsd1 mesodermal
binding to published Lsd1 binding datasets in ES cells and myeloid
cells (Whyte et al, 2012; Kerenyi et al, 2013) showed robust co-
localization of Lsd1 at Scl-bound enhancers (Fig 4G and H) in both
cluster L and R in Flk1+ mesoderm, which is a heterogenous
population of cells committed to hemato-vascular or cardiac fates.
In myeloid cells, cardiac enhancers were devoid of both Lsd1 and
H3K4me1 (Fig 4H), documenting a short temporal window for
Lsd1 action. Nevertheless, analysis of Lsd1 binding in Scl-deficient
mesodermal cells did not show evidence of impaired Lsd1 binding
in cardiac enhancers in Cluster L (Fig 4G and H). These results
imply that, although Lsd1 is likely involved in the decommission-
ing of unused enhancers upon mesodermal lineage diversification,
defective cardiac repression in Scl-deficient mesodermal derivatives
is not caused by an inability to recruit Lsd1 to primed cardiac
enhancers.
Binding by Scl and cardiac Gata4 and/or Hand1 define enhancer
subgroups that may determine fate choice between opposing
mesodermal fates
As the analysis of repressive marks and corepressors provided no
evidence for direct Scl-dependent corepressor recruitment to
enhancers or promoters in mesoderm, we considered the possibil-
ity that Scl inhibits cardiac fate by interfering with the activation
of these genes by cardiac regulators. To identify candidate factors
that could also bind to Scl-regulated enhancers, we performed
DNA motif enrichment analysis for known transcription factor
binding sites in Transfac and Jaspar databases. This analysis iden-
tified the composite Tal1(Scl)_Gata motif and Gata motifs as the
most prevalent motifs in both activated and repressed genes
(Fig 5A).
There are six known Gata factors, of which Gata1, 2 and 3 act
in hematopoietic cells and Gata4, 5 and 6 regulate cardiac devel-
opment (Chlon & Crispino, 2012). Gata4 can regulate cardiac
development both indirectly via endoderm and directly by binding
to cardiac genes in Flk1+ mesoderm (Holtzinger et al, 2010; Oda
et al, 2013). Analysis of a published dataset for Gata4 binding in
Flk1+ mesoderm revealed that Gata4 binding overlaps with a
large fraction (41%) of Scl binding sites (Fig 5B). Moreover, as
other bHLH factors can also bind to E-box motifs similar to Scl,
we also performed ChIP-seq for Hand1, a key cardiac bHLH factor
that can interact with cardiac Gata factors. 13.2% all Scl-bound
enhancers were co-occupied by Scl and Hand1 in Flk1+ mesoderm
(9.7% Scl, Hand1 and Gata4 altogether, and 3.5% Scl and Hand1
alone). Analysis of the regulatory regions for key cardiac (Gata6,
Tbx5 and Myocardin) and hematopoietic (Runx1, Gfi1b and Gata2)
transcription factors identified at least one enhancer in each gene
bound by Scl, Hand1 and/or Gata4 (Fig 5C). The sites that can be
occupied by all three factors (424 sites) included both that remain
active (cluster R, 167 sites) and sites that become decommis-
sioned during hematopoietic development (cluster L, 201 sites),
and they associated with both Scl-dependent activated (128) and
repressed (79) genes. Similar distribution was observed for Scl
binding sites that were shared with Gata4 or Hand1 alone. These
data suggest that a distinct subset of Scl-bound enhancers may be
used by both hematopoietic and cardiac bHLH and Gata transcrip-
tion factors to activate their own lineage or repress a competing
lineage.
We next assessed whether there are any unique features that
sets the ‘dually accessible’ enhancers apart from enhancers bound
by Scl alone. The enhancers bound by both Scl and Gata4 and/or
Hand1 were more evolutionarily conserved as compared to other
Scl mesodermal binding sites (Fig 5D) and showed higher levels of
Scl binding (Fig 5E), H3K4me1, H3K27ac (Fig 5F and G) and Lsd1
enrichment (Fig 5H). Moreover, Scl target genes that harbor an
enhancer that can be bound by Scl and Gata4 and/or Hand1
showed higher average gene expression change in Scl-expressing
WT versus SclKO Flk1+ mesoderm as compared to Scl target genes
that do not have a dually accessible enhancer (Fig 5I). The genes
that contain a dually accessible enhancer included many hemato-
poietic (27/31, 87%) and cardiac (10/15, 67%) transcription
factors (Fig 5J).
We next assessed whether similar developmental stage-specific
binding observed with Scl is also seen with Gata4, for which
several published datasets from fetal and adult stages are avail-
able (He et al, 2014). Analysis of Gata4 binding in different stages
of heart development showed gradual loss of overlap between Scl
mesodermal binding sites and Gata4 binding from Flk1+ mesoderm
to E12.5 hearts to adult hearts (Supplementary Fig S5A and B).
While Gata4 binding was observed in both hematopoietic (Gfi1b
and Myb) and cardiac enhancers (Tbx5 and Gata6) in
mesoderm, hematopoietic enhancers had lost Gata4 binding in
fetal hearts by E12.5. Many cardiac enhancers also lost Gata4
▸Figure 5. A subset of Scl-bound enhancers can be accessed by cardiac transcription factors.A Scl DNA binding motif analysis shows enrichment of Tal1_Gata, Gata and Ets motifs in both Scl activated and repressed genes.
B Venn diagram showing overlaps between Scl, Hand1 and Gata4 (Oda et al, 2013) binding sites in Flk1+ mesoderm documents that some of Scl MES binding sites
are also bound by cardiac TFs.
C Gata4, Hand1 and Scl ChIP-seq tracks with cardiac and hematopoietic gene regions show examples of three subgroups of enhancers—those bound by Scl, Hand1
and Gata4 (gray), Scl and Gata4 (orange) and those bound only by Scl (blue).
D–H Scl binding sites that overlap with both Hand1 and Gata4 (gray) or with Hand1 (green) or Gata 4 (orange) alone show higher evolutionary conservation (D) and
higher average enrichment of Scl (E), H3K4me1 (F), H3K27ac (G) and Lsd1 (H) in mesoderm compared to sites bound by Scl alone (blue).
I Average expression changes between Scl-expressing and Scl-deficient mesoderm shows that genes that are regulated by enhancers bound by all three (Scl,
Hand1 and Gata4) factors or two factors (Scl and Hand1 or Scl and Gata4) show higher absolute expression changes compared to those bound by Scl
alone.
J Analysis of Scl-regulated key hematopoietic and cardiac genes shows that many of them can be bound also by cardiac factors, Scl, Gata4 and Hand1 (orange);
Scl and Hand1 binding (green); Scl and Gata4 binding (orange); and Scl binding alone (blue).
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binding in adult hearts (Supplementary Fig S5C). These data
show that the key genes regulating cardiovascular fate determi-
nation harbor dually accessible enhancers that can be bound by
both hematopoietic and cardiac factors in mesoderm, but are
dynamically remodeled during lineage diversification and matura-
tion. Our data propose that this subset of enhancers may be critical
for initiating the fate choice between competing cardiovascular
lineages.
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Figure 6. Gata1 and 2 are dispensable for cardiac repression, but essential for the emergence of HS/PCs from hemogenic endothelium.
A FACS analysis of day 7 EBs with markers CD41 and c-Kit shows efficient generation of HS/PCs from WT, but not SclKO or Gata1&2KO cells. Average of six independent
experiments with SEM is shown.
B FACS analysis of day 5.25 EBs with markers CD41, Flk1, Tie2 and CD31 shows the generation of hemogenic endothelial cells from WT and Gata1&2KO cells, but not
SclKO cells. Average of five independent biological experiments with SEM is shown.
C Assessment of the developmental potential of day 4.75 EB CD41CD31+Tie2+ endothelial cells on OP9 for 14 days shows the generation of CD45+ hematopoietic cells
from WT cells but not Gata1&2KO or SclKO cells, and troponin T+ cardiomyocytes from SclKO cells, but not WT or Gata1&2KO cells. Average of four independent
experiments with SEM is shown.
D Heatmaps show gene expression differences in subsets of hematopoietic genes between Gata1&2KO and WT or SclKO day 4.75 CD41CD31+Tie2+ endothelial cells.
Cardiac derepression is observed only in SclKO cells. *designates non-functional transcripts.
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Gata1 and/or Gata2 are dispensable for cardiac repression but are
essential for emergence of HS/PCs from hemogenic endothelium
Since Scl and Gata4 share common binding sites in both hematopoi-
etic and cardiac enhancers and Scl acts together with hematopoietic
Gata factors 1 and 2 in blood forming cells, we investigated whether
hematopoietic Gata factors are required for Scl-induced gene activa-
tion and/or repression during mesoderm diversification. ChIP–PCR
for Gata2 showed that, similar to Scl, Hand1 and Gata4, Gata2 binds
to dually accessible enhancers in both hematopoietic and cardiac
transcription factors that are activated or repressed by Scl (Supple-
mentary Fig S5D).
To investigate whether hematopoietic Gata factors function in
Scl-mediated gene activation and repression, we assessed the devel-
opmental potential of Gata1 and 2 double knockout (Gata1&2KO) ES
cells, which eliminates possible redundancy between Gata1 and 2.
No c-Kit+CD41+ hematopoietic progenitors were detected in day 7
Gata1&2KO EBs or SclKO EBs (Fig 6A). However, FACS analysis on
day 5.25 EBs identified a subpopulation of cells in Gata1&2KO EBs
that expressed the early HS/PC marker CD41, while SclKO EBs were
devoid of this population. Nevertheless, all CD41+ cells in
Gata1&2KO EBs co-expressed Flk1 and the majority also expressed
endothelial markers CD31 and Tie2, raising the hypothesis that
HS/PC development becomes stalled at hemogenic endothelium in
the absence of Gata1 and 2 (Fig 6B).
To assess the differentiation potential of Gata1- and 2-deficient
endothelial cells, EBs were differentiated for 4.75 days, after which
CD41CD31+Tie2+ endothelial cells were sorted and cultured for
14 days in hematopoietic and cardiac conditions on OP9 stroma.
Neither Gata1&2KO nor SclKO endothelial cells generated CD45+
hematopoietic cells (Fig 6C). In contrast, only SclKO, but not
Gata1&2KO or WT endothelial cells, robustly differentiated into
troponin T+ cardiomyocytes. These data show that Gata1 and/or 2
is required for hematopoiesis, but not for the repression of cardio-
genesis in endothelial precursors.
To investigate the effect of Gata1 and 2 on endothelial gene
expression, CD41CD31+Tie2+ endothelial cells from day 4.75 EBs
were sorted for RNA sequencing. No significant derepression of
cardiac regulators was observed in Gata1&2KO endothelial cells,
unlike SclKO endothelial cells which showed induction of several
cardiac genes (Fig 6D, Supplementary Table S2). Notably, expression
of many hemato-vascular transcription factors that were down-
regulated in SclKO endothelial cells (e.g. Lyl1, Hhex, Cbfa2t3/Eto2,
Erg, Fli1, Sox7) was not significantly decreased in Gata1&2KO endothe-
lial cells. Likewise, many surface markers of hemogenic endothelium
and HS/PCs (e.g. CD41/Itga2b, VE-cadherin/Cdh5, Esam, Icam2) were
expressed in Gata1&2KO endothelial cells, further supporting the
notion that Gata1&2KO cells can specify hemogenic endothelium.
However, the expression of key HS/PC transcription factors Runx1,
Myb, Gfi1b, Pu.1/Sfpi1 and Klf1 was down-regulated in Gata1&2KO
endothelial cells (Fig 6D), implying that Gata1 and/or 2 is required
for the induction of the hematopoietic transcription factor
network that enables the emergence of HS/PCs from hemogenic
endothelium.
To exclude the possibility that Gata3, a hematopoietic Gata factor
that functions in T cells (Hosoya et al, 2010) and HSC maintenance
(Ku et al, 2012) compensates for Gata1 and 2 in cardiac repression,
Gata1-, 2- and 3-deficient (Gata1&2KOGata3KD) ES cells were
generated using lentiviral knockdown of Gata3. Similar to
Gata1&2KO, Gata1&2KOGata3KD endothelial cells showed neither up-
regulation of cardiac program nor generation of ectopic cardiomyo-
cytes in culture, and the hematopoietic program was similarly
stalled at hemogenic endothelium with intact expression of many
Scl-dependent hemato-vascular genes (Hhex, Ets2, Lyl1, Itga2b/
CD41, Cadh5/Ve-Cad etc) and defective expression of key HS/PC
transcription factors (e.g. Runx1 and Myb) (Supplementary Fig S6).
Collectively, these data show that hematopoietic Gata factors are
critical for full activation of Scl-dependent hematopoietic transcrip-
tional network, but not for cardiac repression.
Gata factors 1 and 2 recruit Scl to specific binding sites in key
hematopoietic transcription factors
To investigate whether loss of Gata1 and Gata2 compromises Scl
binding to its targets during mesoderm specification, we determined
genome-wide Scl binding sites in Flk1+ mesoderm from Gata1&2KO
EBs using ChIP-seq (Fig 7A, Supplementary Table S3). The GO
terms enriched among the genes associated with overlapping Scl
binding sites included both hematopoiesis and cardiogenesis, while
the peaks lost in Gata1&2KO cells were associated with genes related
to hematopoiesis (Fig 7A). Analysis of the individual genes
confirmed intact Scl binding to key cardiac enhancers (Myocardin,
Gata4 and Gata6) in the absence of Gata1 and 2 (Fig 7B, Supple-
mentary Fig S7B). Likewise, a majority of hemato-vascular tran-
scription factors (Lyl1, Fli1) that were expressed in Gata1&2KO
endothelium retained Scl binding (Fig 7C). The subset of genes that
lost an Scl binding site in Gata1&2KO Flk1+ cells included transcrip-
tion factors Runx1, Myb, Pu.1/Sfpi1 and Gfi1b, whose expression in
endothelium was Gata1 and 2 dependent (Fig 7D, Supplementary
Fig S7B). Remarkably, while several other Scl binding sites were
preserved near Runx1 gene, the binding site that was lost in
Gata1&2KO cells corresponds to +23 enhancer that has been shown
to be essential for Runx1 regulation during HSC emergence
(Nottingham et al, 2007) and becomes the strongest Scl binding site
in HPC7 hematopoietic progenitor cells (Supplementary Fig S3B).
These results imply that although Gata1 and 2 are not essential for
Scl binding to the majority of its activated or repressed target genes,
they are required for the recruitment of Scl to specific regulatory
regions that govern the expression of key hematopoietic transcrip-
tion factors. ChIP-PCR for Gata1&2KOGata3KD mesoderm confirmed
similar binding for Scl in key hematopoietic and cardiac enhancers
in the absence of all three hematopoietic Gata factors (Supplemen-
tary Fig S7A).
We also assessed whether the hematopoietic Gata factors func-
tion by modifying the epigenetic landscape to enable access of Scl
complex to key hematopoietic enhancers. Analysis of H3K4me1 and
H3K27ac in Gata1- and 2-deficient mesodermal cells did not reveal
differences in the establishment of primed state in key hematopoi-
etic and cardiac enhancers, including those that could not be acti-
vated in Gata1&2KO cells (Supplementary Fig S7B). Likewise, there
was a strong correlation of global H3K4me1 and H3K27ac levels
between WT and Gata1&2KO Flk1+ mesoderm (Supplementary Fig
S7C). Collectively, these data show that Scl and hematopoietic Gata
factors bind to enhancers that have been epigenetically primed for
activation in mesoderm prior to their binding. While the repression
of the cardiac fate by Scl can occur in the absence of hematopoietic
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Gata factors, they help recruit Scl to new regulatory regions to
enable activation of key hematopoietic transcription factors that
secure the emergence of HS/PCs from hemogenic endothelium.
Discussion
The ability to execute developmental fate decisions with proper
temporal and spatial control is critical for embryonic development,
as well as for harnessing the power of stem cell and reprogramming
technologies for therapeutic applications. The bHLH factor Scl has
emerged as a true master regulator of mesoderm fate as it not only
governs the establishment of the entire hematopoietic system, but it
also is critical for preventing ectopic cardiomyocyte development in
hemogenic tissues (Van Handel et al, 2012). Here we show that Scl
directly binds to enhancers regulating a broad network of hemato-
poietic and cardiac transcription factors to specify the hematopoietic
lineage and override the cardiac fate and thus has a dual function in
coordinating the segregation of multipotent cardiovascular meso-
derm to downstream cell fates.
We discovered that Scl regulates mesodermal fates by binding to
enhancers that have been primed for activation specifically in Flk1+
mesoderm. A previous study with DNA binding mutant of Scl
showed that 80% of Scl peaks in erythroid cells were lost in the
mutant and could neither be bound by Scl’s interaction partner
Gata1, raising the question whether Scl acts as a pioneer factor at
these sites (Kassouf et al, 2010). Our finding that the establishment
of the active histone modifications, H3K4me1 and H3K27ac, at the
enhancers of Scl’s hematopoietic and cardiac target genes occurs
independent of Scl and its complex partners Gata1 and 2 implies
that these factors do not act as a pioneer factors but rather exploit
pre-established enhancers in mesoderm. These results suggest that
yet another factor(s) is responsible for establishing primed enhanc-
ers that can attract Scl and Gata factors to their cell type-specific
binding sites. Our data are consistent with a model that the acquisi-
tion of a primed, or provisionally activated, state at hematopoietic
and cardiac enhancers precedes Scl and Gata1 and 2 binding and
determines the available fate options in mesoderm. Our finding that
overexpression of Scl in ES cells did not lead to Scl binding to hema-
topoietic or cardiac enhancers also supports this model.
Several recent studies have documented highly cell type-specific,
functional Scl binding during later stages of hematopoietic develop-
ment (Calero-Nieto et al, 2014; Pimkin et al, 2014; Wu et al, 2014).
Our study documents the dynamic nature of Scl binding already in
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Figure 7. Gata1 and/or Gata2 modulates Scl binding in the enhancers of key hematopoietic transcription factors.
A Intersection of Scl binding sites in WT and Gata1&2KO Flk1+ MES shows Gata1- and/or Gata2-dependent redistribution of Scl binding sites in a subset of target
genes (two independent experiments). Selected GO terms among top 10 most enriched for Gata-independent (blue) and Gata-dependent (purple) Scl binding sites
together with example genes reveal Gata1- and/or Gata2-dependent functions for Scl-mediated hematopoietic regulation.
B–D Scl ChIP-seq tracks in WT and Gata1&2KO Flk1+ MES show Gata1- and 2-independent Scl binding to cardiac regulators (Myocardin, Gata4) (B), Gata1- and
2-independent Scl binding to key hemato-vascular regulators (Lyl1, Fli1) (C) and Gata1- and/or 2-dependent Scl binding to key HS/PC transcription factors
(Myb, Runx1) (D).
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mesoderm. In contrast to the key hematopoietic enhancers that
retained Scl binding and active epigenetic marks throughout hema-
topoietic development, Scl binding to cardiac enhancers was
restricted to Flk1+mesoderm and correlated with the transient pres-
ence of active histone marks. These data imply that Scl represses
the cardiac fate during a brief window of developmental plasticity
before mesodermal fates become solidified, providing a molecular
basis for the inducible loss-of-function studies that narrowed down
the temporal requirement for Scl function in cardiac repression to
mesoderm/early angioblasts (Van Handel et al, 2012). Moreover,
these data suggest enhancer decommissioning as a key mechanism
that extinguishes the cardiac fate option in hematopoietic cells.
Our studies propose a model that Scl suppresses cardiogenesis by
interfering with the activation of key cardiac genes until the ‘window
of opportunity’ for their activation is closed, rather than directly
recruiting corepressors. Analyses correlating Scl binding with major
corepressors and repressive epigenetic marks (H3K27me3, H3K9me3
and DNA methylation) did not provide a mechanism by which tran-
sient Scl binding to these enhancers results in the repression of
cardiac genes, but rather suggests that these repression mechanisms
contribute to the overall gene silencing later, once the Scl-driven
lineage choice decision has already been made.
Lsd1 emerged as a key candidate for modulating enhancer
activity during mesoderm diversification as it decommissions cell
type-specific enhancers by demethylating H3K4me1 in several
developmental contexts including ES cells and myeloid cells (Whyte
et al, 2012; Kerenyi et al, 2013), and interaction of Scl with Lsd1
has been implicated in erythroid progenitors and T-ALL (Hu et al,
2009a,b; Li et al, 2012). Our analysis verified a strong correlation
between Lsd1 and Scl binding sites and H3K4me1 in mesoderm.
However, Lsd1 binding to cardiac enhancers was not impaired in
Scl-deficient cells. Thus, although Lsd1 is involved in decommis-
sioning of unused enhancers during mesoderm diversification, its
recruitment to cardiac enhancers is not Scl dependent. These data
do not, however, exclude the possibility that the function of Lsd1,
or the COREST complex Lsd1 is part of, may be influenced by Scl.
As acetylation can impede Lsd1 function (Amente et al, 2013), it is
plausible that Scl binding at hematopoietic enhancers reinforces a
fully active state, possibly by chromosomal looping to promoter,
and thereby indirectly impairs Lsd1 function. On the other hand, Scl
binding at cardiac enhancers may interfere with chromosomal
looping and/or the establishment of a proper cardiac activation
complex, enabling Lsd1 to decommission cardiac enhancers. Future
studies are required to directly test these hypotheses.
Our findings that there is substantial overlap with Scl and Hand1
and/or Gata4 mesodermal binding sites, and essentially all major
hematopoietic and cardiac transcription factors that are regulated by
Scl contain at least one enhancer that can also be bound by Hand1
and/or Gata4, support the model that repression of an alternative
fate choice may be the result of preventing activation of these genes
by competing lineage-specific regulators. The subset of Scl-bound
enhancers that can also be bound by Hand1 and/or Gata4 showed
higher evolutionary conservation, higher H3K4me1 and H3K27ac
enrichment and Lsd1 binding in mesoderm, and stronger correlation
with Scl-dependent gene expression change. We propose that these
dually accessible enhancers that can be regulated by factors of two
opposing lineages act as a platform where the fate choice is deter-
mined. Future studies will determine which cardiac factor(s) is
most critical for activating these cardiac enhancers and whether
they are also critical for suppressing the hematopoietic program.
We found that Gata2 can bind together with Scl to both hemato-
poietic and cardiac enhancers; however, we discovered that hemato-
poietic Gata factors (1, 2 and 3) are dispensable for Scl-mediated
cardiac repression, and only necessary for recruiting Scl to specific
binding sites to activate hematopoietic factors required for HS/PC
emergence and differentiation (Runx1, Pu.1/Sfpi1, Klf1, Gfi1b).
These data suggest that although the core Gata/Scl complex can
bind to both activated and repressed genes, Gata/Scl interaction
becomes critical principally in gene activation. Similar to hemato-
poietic Gata factors, Runx1 can redistribute Scl to new binding sites
as development progresses from endothelium to HS/PCs (Lichtinger
et al, 2012). Thus, Scl establishes the blood lineage by binding to a
broad set of hematopoietic enhancers; it then induces downstream
transcriptional network with the help of its target genes, which
enable Scl to relocate to new binding sites to build a functional
hematopoietic system.
The findings that Scl targets Gata1, Gata2 and Runx1 (Van
Handel et al, 2012), which are critical for modulating Scl activity in
hematopoietic genes, are not essential for cardiac repression
underscore the unique role of Scl as a dual regulator of hematopoi-
etic versus cardiac fate choice. Apart from the studies with Scl,
ectopic cardiogenesis in hemato-vascular mesoderm has only been
observed upon ablation of Etv2, the upstream regulator for Scl (Ren
et al, 2010; Palencia-Desai et al, 2011; Rasmussen et al, 2011; Liu
et al, 2012; Wareing et al, 2012). Future studies will be required to
determine whether Etv2 has a specific function in silencing cardiac
fate or whether it contributes indirectly by inducing Scl expression.
Our finding that Scl directs mesoderm diversification via enhanc-
ers is concordant with the data that transcription factor binding at
enhancers is a key determinant of tissue-specific gene expression
(Heintzman et al, 2009; Visel et al, 2009; Xu et al, 2012). Our
discovery that Scl directly binds to enhancers of key transcription
factors of two alternative fates suggests a mechanism by which line-
age-specific transcription factors secure a mutually exclusive lineage
choice by both activating their own lineage and preventing the
establishment of alternative fates. Coordination of both processes by
the same factor enables accurate fate specification and prevents the
generation of a cell with mixed characteristics. As reprogramming of
induced pluripotent stem cells is also initiated at enhancers (Soufi
et al, 2012), understanding the repressive function of master regula-
tors may have broader implications in regenerative medicine as the
presence of a factor that could block lineage-specific enhancers
during lineage reprogramming may influence the efficiency and
outcome of reprogramming. Thus, better understanding of the pre-
requisites for gene activation and repression by master regulators,
and how the epigenetic boundaries are created between cell types,
will help develop more effective protocols for directing cell fates for
therapeutic applications.
Materials and Methods
ES cell culture and differentiation
Standard ES cell culture conditions were used to maintain SclhCD4
(Chung et al, 2002), SclKO (Porcher et al, 1996), SclKOiScl, WT,
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Gata1&2KO and Gata1&2KOGata3KD ES cells. SclKOiScl cell line was
generated by transduction of SclKO ES cells with rtTA and PNL1-Scl-GFP
lentiviral vectors followed by clonal selection. Gata1&2 KOGata3KD
ES cells were generated by transducing Gata1&2KO ES cells with
Gata3 shRNA lentiviral vector (Santa Cruz). Flk1+ mesoderm and
hemato-vascular derivatives were generated using EB differentiation
as described (Mikkola et al, 2003). EBs were digested enzymatically
and analyzed by FACS or enriched for desired populations by
MACS or FACS sorting. For further details about cell culture, see
Supplementary Materials and Methods.
Gene expression analysis
RNA preparation, hybridization to Mouse Genome 430 2.0 arrays,
and analysis was conducted as described previously (Van Handel
et al, 2012). Libraries for RNA sequencing were constructed using
Encore Complete RNA-Seq DR Multiplex System 1-8 (Nugen).
Libraries were sequenced using HIseq-2000 (Illumina). Reads were
mapped to mouse genome (mm9) using TopHat v2.0.4 (Trapnell
et al, 2009). Abundance estimations (FPKMs) were performed with
Cufflinks v2.0.1 (Trapnell et al, 2010). Assemblies for all samples
were merged using Cuffmerge, and differential expression (P < 0.01)
was determined using Cuffdiff. Quantitative reverse-transcriptase
polymerase chain reaction (qRT–PCR) was performed with Light-
Cycler 480 SYBR Green I Master (Roche) using LightCycler 480
(Roche). Primer sequences are listed in Supplementary Table S4. For
further details, see Supplementary Materials and Methods.
Chromatin immunoprecipitation sequencing analysis
ChIP with ES, Flk1+ mesodermal (MES), HPC7, MEL or HL1 cells
were performed as described previously (Ferrari et al, 2012; Kerenyi
et al, 2013). Libraries were generated using Nugen Ovation ultralow
kit and sequenced using HIseq-2000 (Illumina). Mapping was
performed using Bowtie (Langmead et al, 2009) as described (Ferrari
et al, 2012). Peak identification was performed with MACS v1.3.7.1
(Zhang et al, 2008). For published ChIP-seq datasets used and more
detailed methods, see Supplementary Materials and Methods.
Reduced representation bisulfite sequencing
RRBS libraries were generated from genomic DNA of mouse ES
cells, WT and SclKO Flk1+ mesoderm (MES) and MEL cells as
described previously (Meissner et al, 2005) with minor modifica-
tions. RRBS data were aligned with BS-Seeker2 (Guo et al, 2013).
Differentially methylated cytosines were calculated with methylKit
(Akalin et al, 2012). For detailed methods and the published
genome-wide methylation datasets used in this study, see Supple-
mentary Materials and Methods.
Analysis of endothelial differentiation potential
After 4.75 days of EB induction, CD41CD31+Tie2+cells were sorted
from WT, SclKO, SclKOiScl, Gata1&2KO and Gata1&2KO Gata3KD EBs
and 20,000 cells were plated on irradiated OP9 stroma in 8-well
chamber slides (354118 BD FalconTM). 1 mg/ml doxycycline
(1:1,000) is added to SclKOiScl culture and is kept on since day 2 of
EB induction. The media contained a-MEM, 20% FBS, 1% penicillin,
streptomycin and 1% glutamine. For hematopoietic differentiation,
50 ng/ml SCF, 5 ng/ml IL3, 5 ng/ml IL6, 5 ng/ml TPO and 10 ng/ml
Flt3L were added. For cardiac differentiation, 5 ng/ml hVEGF,
30 ng/ml mFGF, 50 ng/ml hBMP4 and 1 lM Wnt/Beta-Catenin
Inhibitor XAV939 (Sigma) were added. After 14 days, FACS staining
or immunostaining was performed as described (Van Handel et al,
2012). See Supplementary Materials and Methods for details.
Accession numbers
Microarray, ChIP-seq, RNA-seq and RRBS datasets have been depos-
ited to the NCBI GEO database under the accession number
GSE47085. All datasets used in this study are listed in Supplemen-
tary Table S5.
Supplementary information for this article is available online:
http://emboj.embopress.org
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